Consistency of Bordetella pertussis vaccine seed strains and potency of whole-cell pertussis vaccine still in use in Poland

Zawadka, Monika; Mosiej, Ewa; Polak, Maciej; Krysztopa-Grzybowska, Katarzyna; Moskala, Bozena; Rokosz‐Chudziak, Natalia; Rabczenko, Daniel; Augustynowicz, Ewa; Lutyńska, Anna

doi:10.1016/j.biologicals.2013.11.006

Cited by 6 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only two Polish isolates were available in 2007–2012, both of which were Fim2. The Polish WCV is derived from strains which produce both Fim2 and Fim3 [ 49 ]. One strain, isolated in Spain in 2010, was found to be auto-agglutinable (data not shown).…”

Section: Resultsmentioning

confidence: 99%

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012

Gent

Heuvelman

Heide

et al. 2014

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Despite more than 50 years of vaccination, pertussis is still an endemic disease, with regular epidemic outbreaks. With the exception of Poland, European countries have replaced whole-cell vaccines (WCVs) by acellular vaccines (ACVs) in the 1990s. Worldwide, antigenic divergence in vaccine antigens has been found between vaccine strains and circulating strains. In this work, 466 Bordetella pertussis isolates collected in the period 1998–2012 from 13 European countries were characterised by multi-locus antigen sequence typing (MAST) of the pertussis toxin promoter (ptxP) and of the genes coding for proteins used in the ACVs: pertussis toxin (Ptx), pertactin (Prn), type 2 fimbriae (Fim2) and type 3 fimbriae (Fim3). Isolates were further characterised by fimbrial serotyping, multi-locus variable-number tandem repeat analysis (MLVA) and pulsed-field gel electrophoresis (PFGE). The results showed a very similar B. pertussis population for 12 countries using ACVs, while Poland, which uses a WCV, was quite distinct, suggesting that ACVs and WCVs select for different B. pertussis populations. This study forms a baseline for future studies on the effect of vaccination programmes on B. pertussis populations.Electronic supplementary materialThe online version of this article (doi:10.1007/s10096-014-2297-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012

Gent

Heuvelman

Heide

et al. 2014

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

“…The last vaccine strain composition change took place in 1978 and was aimed at eliminating strains expressing the highest toxicity. Quality measures on wP vaccine lots manufactured and widely used in Poland confirmed the expected activity and manufacturing consistency [32,33]. We can speculate that the structure of the B. pertussis population in Poland might change in the future in a more narrow direction, as the currently used vaccine strain composition has been in use for 35 years.…”

Section: Discussionmentioning

confidence: 76%

Sequence variation in virulence-related genes of Bordetella pertussis isolates from Poland in the period 1959–2013

Mosiej

Zawadka

Krysztopa-Grzybowska

et al. 2014

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

This study aimed to characterise Bordetella pertussis isolates circulating in Poland since 1959. Sequence analysis of ptxA, ptxC, prn, tcfA, fim2, fim3 and ptxP for 175 clinical isolates and currently and previously used vaccine strains was performed. Clinical isolates from the period 1995-2013 were found to be different to three currently used vaccine strains harbouring the allelic combination ptxA2-ptxC1-ptxP1-prn1-tcfA2-fim2-1-fim3-1, seen frequently in Poland in the early pertussis vaccination period but not found after 1995. Generally, among B. pertussis isolates from the period 2000-2013, two genotypes predominated, ptxA1-ptxC1-ptxP1-prn1-tcfA2-fim2-2-fim3-1 and ptxA1-ptxC1-ptxP1-prn2-tcfA2-fim2-1-fim3-1, with frequencies of 45% and 32.5%, respectively. The isolates harbouring ptxA1-ptxC2-ptxP3-prn2-tcfA2-fim2-1-fim3-2 and ptxA1-ptxC2-ptxP3-prn2-tcfA2-fim2-1-fim3-1 profiles, currently highly prevalent within other European Union (EU) countries, were rarely found in Poland, as they circulated in the period 2000-2013 with frequencies of 10% and 5%, respectively. We hypothesise that several previous changes of strain composition in whole-cell pertussis vaccine produced locally and used since 1960 in Poland resulted in a more diverse immune pressure in the population, resulting in different prevalence of alleles compared to elsewhere.

show abstract

“…The Kendrick model has a long history of use as a standard release test and has been used extensively to demonstrate consistency in vaccine lot manufacturing [19] The potency data from this model are sensitive enough to detect the differences when vaccine strains were changed or IU lowered during production [20]. [11].…”

Section: Discussionmentioning

confidence: 99%

The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines

Queenan

Fernandez

Shang

et al. 2014

Expert Review of Vaccines

View full text Add to dashboard Cite

The mouse nasopharyngeal challenge model could be considered as a potency and release assay for wP vaccines. Whether this model directly correlates with clinical vaccine efficacy requires further investigations. Whether this model directly correlates with clinical vaccine efficacy requires further investigations. The mouse nasopharyngeal challenge model could be considered as a potency and release assay for wP vaccines.

show abstract

Consistency of Bordetella pertussis vaccine seed strains and potency of whole-cell pertussis vaccine still in use in Poland

Cited by 6 publications

References 23 publications

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012

Sequence variation in virulence-related genes of Bordetella pertussis isolates from Poland in the period 1959–2013

The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines

Contact Info

Product

Resources

About